DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Patients with advanced HER2-positive unresectable and/or metastatic breast cancer previously treated with ado-trastuzumab emtansine who received trastuzumab deruxtecan experienced a median PFS of 17.8 months, compared with 6.9 months among those who received physician’s choice of treatment HR, 0.3589; 95% CI, 0.2840-0.4535; P < .0000001), according to data from the phase 3 DESTINY-Breast02 trial presented during the 2022 San Antonio Breast Cancer Symposium.